James A. Rodrigues
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
James A. Rodrigues has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- David B. Solit
Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
5 shared publications - Amber J. Kiliti
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York
4 shared publications Aphrothiti J. Hanrahan
4 shared publications- Barry S. Taylor
Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY
4 shared publications - Brett S. Carver
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, USA
4 shared publications - Emmet Jordan
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York
4 shared publications
Latest Publications
- 12 November 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- p. OF1-OF3
Location, Location, Location: Membranous Nectin-4 as a Biomarker for Enfortumab Vedotin
Summary: Combination therapy with enfortumab vedotin (EV), a Nectin-4–targeted antibody–drug conjugate (ADC), and pembrolizumab, an anti–PD-1 antibody, recently supplanted platinum-based chemotherapy as the standard first-line systemic therapy for patients with muscle-invasive or metastatic urothelial cancer. A composite biomarker integrating membranous Nectin-4 expression and NECTIN4 gene amplification is predictive of response to EV. See related article by Klümper et al., p. XX .
- 12 November 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- p. OF1-OF3
Location, Location, Location: Membranous Nectin-4 as a Biomarker for Enfortumab Vedotin
Summary: Combination therapy with enfortumab vedotin (EV), a Nectin-4–targeted antibody–drug conjugate (ADC), and pembrolizumab, an anti–PD-1 antibody, recently supplanted platinum-based chemotherapy as the standard first-line systemic therapy for patients with muscle-invasive or metastatic urothelial cancer. A composite biomarker integrating membranous Nectin-4 expression and NECTIN4 gene amplification is predictive of response to EV. See related article by Klümper et al., p. XX .
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from AKT1 E17K Inhibits Cancer Cell Migration by Abrogating β-Catenin Signaling
Mutational activation of the PI3K/AKT pathway is among the most common pro-oncogenic events in human cancers. The clinical utility of PI3K and AKT inhibitors has, however, been modest to date. Here, we used CRISPR-mediated gene editing to study the biological consequences of AKT1 E17K mutation by developing an AKT1 E17K–mutant isogenic system in a TP53-null background. AKT1 E17K expression under the control of its endogenous promoter enhanced cell growth and colony formation, but had a paradoxical inhibitory effect on cell migration and invasion. The mechanistic basis by which activated AKT1 inhibited cell migration and invasion was increased E-cadherin expression mediated by suppression of ZEB1 transcription via altered β-catenin subcellular localization. This phenotypic effect was AKT1-specific, as AKT2 activation had the opposite effect, a reduction in E-cadherin expression. Consistent with the opposing effects of AKT1 and AKT2 activation on E-cadherin expression, a pro-migratory effect of AKT1 activation was not observed in breast cancer cells with PTEN loss or expression of an activating PIK3CA mutation, alterations which induce the activation of both AKT isoforms. The results suggest that the use of AKT inhibitors in patients with breast cancer could paradoxically accelerate metastatic progression in some genetic contexts and may explain the frequent coselection for CDH1 mutations in AKT1-mutated breast tumors.Implications:AKT1 E17K mutation in breast cancer impairs migration/invasiveness via sequestration of β-catenin to the cell membrane leading to decreased ZEB1 transcription, resulting in increased E-cadherin expression and a reversal of epithelial–mesenchymal transition.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from AKT1 E17K Inhibits Cancer Cell Migration by Abrogating β-Catenin Signaling
Mutational activation of the PI3K/AKT pathway is among the most common pro-oncogenic events in human cancers. The clinical utility of PI3K and AKT inhibitors has, however, been modest to date. Here, we used CRISPR-mediated gene editing to study the biological consequences of AKT1 E17K mutation by developing an AKT1 E17K–mutant isogenic system in a TP53-null background. AKT1 E17K expression under the control of its endogenous promoter enhanced cell growth and colony formation, but had a paradoxical inhibitory effect on cell migration and invasion. The mechanistic basis by which activated AKT1 inhibited cell migration and invasion was increased E-cadherin expression mediated by suppression of ZEB1 transcription via altered β-catenin subcellular localization. This phenotypic effect was AKT1-specific, as AKT2 activation had the opposite effect, a reduction in E-cadherin expression. Consistent with the opposing effects of AKT1 and AKT2 activation on E-cadherin expression, a pro-migratory effect of AKT1 activation was not observed in breast cancer cells with PTEN loss or expression of an activating PIK3CA mutation, alterations which induce the activation of both AKT isoforms. The results suggest that the use of AKT inhibitors in patients with breast cancer could paradoxically accelerate metastatic progression in some genetic contexts and may explain the frequent coselection for CDH1 mutations in AKT1-mutated breast tumors.Implications:AKT1 E17K mutation in breast cancer impairs migration/invasiveness via sequestration of β-catenin to the cell membrane leading to decreased ZEB1 transcription, resulting in increased E-cadherin expression and a reversal of epithelial–mesenchymal transition.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures 1-12, Supplementary Tables 1-3 from AKT1 E17K Inhibits Cancer Cell Migration by Abrogating β-Catenin Signaling
S1. Generation of MCF-10A isogenic cells via TP53 knockout and AKT1 E17K knock-in. S2. Frequent co-occurrence of AKT1, TP53 and CDH1 mutations in breast cancers. S3. TP53 CRISPR knockout in MCF-10A cells. S4. Phosphorylation of the AKT1 effector PRAS40 was AKT-dependent in MCF-10A p53ko/E17K cells. S5. Immunofluorescence using a pT308 specific AKT1 antibody of MCF-10A cells following lentiviral infection with V5 tagged (V5 tag) wildtype (WT) or E17K mutant AKT1. S6. Knock-in of the AKT1 E17K mutation did not enhance sensitivity to the pan-AKT kinase inhibitor AZD5363 or the allosteric pan-AKT inhibitor MK2206 in 2Dculture conditions. S7. Survey of previously postulated mechanisms for AKT1-mediated inhibition of cell migration in breast cancer cells. S8. CDH1 promoter methylation status in the MCF-10A isogenic cells. S9. β-catenin interacts with the kinase domain of AKT1. S10. Expression of AKT1 E17K decreased phosphorylation of AKT2 in MCF-10A cells. S11. AKT2 knockdown induces E-cadherin expression in MCF-10A p53ko cells. S12. Model of the mechanism of paradoxical inhibition of cell migration by activated AKT1. Table S1. List of oligonucleotide sequences Table S2. List of antibodies Table S3. List of plasmids
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures 1-12, Supplementary Tables 1-3 from AKT1 E17K Inhibits Cancer Cell Migration by Abrogating β-Catenin Signaling
S1. Generation of MCF-10A isogenic cells via TP53 knockout and AKT1 E17K knock-in. S2. Frequent co-occurrence of AKT1, TP53 and CDH1 mutations in breast cancers. S3. TP53 CRISPR knockout in MCF-10A cells. S4. Phosphorylation of the AKT1 effector PRAS40 was AKT-dependent in MCF-10A p53ko/E17K cells. S5. Immunofluorescence using a pT308 specific AKT1 antibody of MCF-10A cells following lentiviral infection with V5 tagged (V5 tag) wildtype (WT) or E17K mutant AKT1. S6. Knock-in of the AKT1 E17K mutation did not enhance sensitivity to the pan-AKT kinase inhibitor AZD5363 or the allosteric pan-AKT inhibitor MK2206 in 2Dculture conditions. S7. Survey of previously postulated mechanisms for AKT1-mediated inhibition of cell migration in breast cancer cells. S8. CDH1 promoter methylation status in the MCF-10A isogenic cells. S9. β-catenin interacts with the kinase domain of AKT1. S10. Expression of AKT1 E17K decreased phosphorylation of AKT2 in MCF-10A cells. S11. AKT2 knockdown induces E-cadherin expression in MCF-10A p53ko cells. S12. Model of the mechanism of paradoxical inhibition of cell migration by activated AKT1. Table S1. List of oligonucleotide sequences Table S2. List of antibodies Table S3. List of plasmids
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures 1-12, Supplementary Tables 1-3 from AKT1 E17K Inhibits Cancer Cell Migration by Abrogating β-Catenin Signaling
S1. Generation of MCF-10A isogenic cells via TP53 knockout and AKT1 E17K knock-in. S2. Frequent co-occurrence of AKT1, TP53 and CDH1 mutations in breast cancers. S3. TP53 CRISPR knockout in MCF-10A cells. S4. Phosphorylation of the AKT1 effector PRAS40 was AKT-dependent in MCF-10A p53ko/E17K cells. S5. Immunofluorescence using a pT308 specific AKT1 antibody of MCF-10A cells following lentiviral infection with V5 tagged (V5 tag) wildtype (WT) or E17K mutant AKT1. S6. Knock-in of the AKT1 E17K mutation did not enhance sensitivity to the pan-AKT kinase inhibitor AZD5363 or the allosteric pan-AKT inhibitor MK2206 in 2Dculture conditions. S7. Survey of previously postulated mechanisms for AKT1-mediated inhibition of cell migration in breast cancer cells. S8. CDH1 promoter methylation status in the MCF-10A isogenic cells. S9. β-catenin interacts with the kinase domain of AKT1. S10. Expression of AKT1 E17K decreased phosphorylation of AKT2 in MCF-10A cells. S11. AKT2 knockdown induces E-cadherin expression in MCF-10A p53ko cells. S12. Model of the mechanism of paradoxical inhibition of cell migration by activated AKT1. Table S1. List of oligonucleotide sequences Table S2. List of antibodies Table S3. List of plasmids
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures 1-12, Supplementary Tables 1-3 from AKT1 E17K Inhibits Cancer Cell Migration by Abrogating β-Catenin Signaling
S1. Generation of MCF-10A isogenic cells via TP53 knockout and AKT1 E17K knock-in. S2. Frequent co-occurrence of AKT1, TP53 and CDH1 mutations in breast cancers. S3. TP53 CRISPR knockout in MCF-10A cells. S4. Phosphorylation of the AKT1 effector PRAS40 was AKT-dependent in MCF-10A p53ko/E17K cells. S5. Immunofluorescence using a pT308 specific AKT1 antibody of MCF-10A cells following lentiviral infection with V5 tagged (V5 tag) wildtype (WT) or E17K mutant AKT1. S6. Knock-in of the AKT1 E17K mutation did not enhance sensitivity to the pan-AKT kinase inhibitor AZD5363 or the allosteric pan-AKT inhibitor MK2206 in 2Dculture conditions. S7. Survey of previously postulated mechanisms for AKT1-mediated inhibition of cell migration in breast cancer cells. S8. CDH1 promoter methylation status in the MCF-10A isogenic cells. S9. β-catenin interacts with the kinase domain of AKT1. S10. Expression of AKT1 E17K decreased phosphorylation of AKT2 in MCF-10A cells. S11. AKT2 knockdown induces E-cadherin expression in MCF-10A p53ko cells. S12. Model of the mechanism of paradoxical inhibition of cell migration by activated AKT1. Table S1. List of oligonucleotide sequences Table S2. List of antibodies Table S3. List of plasmids
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from AKT1 E17K Inhibits Cancer Cell Migration by Abrogating β-Catenin Signaling
Mutational activation of the PI3K/AKT pathway is among the most common pro-oncogenic events in human cancers. The clinical utility of PI3K and AKT inhibitors has, however, been modest to date. Here, we used CRISPR-mediated gene editing to study the biological consequences of AKT1 E17K mutation by developing an AKT1 E17K–mutant isogenic system in a TP53-null background. AKT1 E17K expression under the control of its endogenous promoter enhanced cell growth and colony formation, but had a paradoxical inhibitory effect on cell migration and invasion. The mechanistic basis by which activated AKT1 inhibited cell migration and invasion was increased E-cadherin expression mediated by suppression of ZEB1 transcription via altered β-catenin subcellular localization. This phenotypic effect was AKT1-specific, as AKT2 activation had the opposite effect, a reduction in E-cadherin expression. Consistent with the opposing effects of AKT1 and AKT2 activation on E-cadherin expression, a pro-migratory effect of AKT1 activation was not observed in breast cancer cells with PTEN loss or expression of an activating PIK3CA mutation, alterations which induce the activation of both AKT isoforms. The results suggest that the use of AKT inhibitors in patients with breast cancer could paradoxically accelerate metastatic progression in some genetic contexts and may explain the frequent coselection for CDH1 mutations in AKT1-mutated breast tumors.Implications:AKT1 E17K mutation in breast cancer impairs migration/invasiveness via sequestration of β-catenin to the cell membrane leading to decreased ZEB1 transcription, resulting in increased E-cadherin expression and a reversal of epithelial–mesenchymal transition.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from AKT1 E17K Inhibits Cancer Cell Migration by Abrogating β-Catenin Signaling
Mutational activation of the PI3K/AKT pathway is among the most common pro-oncogenic events in human cancers. The clinical utility of PI3K and AKT inhibitors has, however, been modest to date. Here, we used CRISPR-mediated gene editing to study the biological consequences of AKT1 E17K mutation by developing an AKT1 E17K–mutant isogenic system in a TP53-null background. AKT1 E17K expression under the control of its endogenous promoter enhanced cell growth and colony formation, but had a paradoxical inhibitory effect on cell migration and invasion. The mechanistic basis by which activated AKT1 inhibited cell migration and invasion was increased E-cadherin expression mediated by suppression of ZEB1 transcription via altered β-catenin subcellular localization. This phenotypic effect was AKT1-specific, as AKT2 activation had the opposite effect, a reduction in E-cadherin expression. Consistent with the opposing effects of AKT1 and AKT2 activation on E-cadherin expression, a pro-migratory effect of AKT1 activation was not observed in breast cancer cells with PTEN loss or expression of an activating PIK3CA mutation, alterations which induce the activation of both AKT isoforms. The results suggest that the use of AKT inhibitors in patients with breast cancer could paradoxically accelerate metastatic progression in some genetic contexts and may explain the frequent coselection for CDH1 mutations in AKT1-mutated breast tumors.Implications:AKT1 E17K mutation in breast cancer impairs migration/invasiveness via sequestration of β-catenin to the cell membrane leading to decreased ZEB1 transcription, resulting in increased E-cadherin expression and a reversal of epithelial–mesenchymal transition.